JDRF T1D Fund logo

JDRF T1D Fund

North America, Massachusetts, United States, Boston

Description

A venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities.

Investor Profile

JDRF T1D Fund has made 48 investments, with 2 in the past 12 months and 21% as lead.

Stage Focus

  • Series A (31%)
  • Series B (21%)
  • Series Unknown (19%)
  • Post Ipo Equity (8%)
  • Series C (8%)
  • Seed (8%)
  • Series D (2%)
  • Grant (2%)

Country Focus

  • United States (79%)
  • Canada (8%)
  • France (6%)
  • Italy (2%)
  • United Kingdom (2%)
  • Israel (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Medical
  • Pharmaceutical
  • Medical Device
  • Biopharma
  • Diabetes
  • Artificial Intelligence (Ai)
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does JDRF T1D Fund frequently co-invest with?

Narya Capital
North America, Ohio, United States, Columbus
Co-Investments: 3
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 5
Bluebird Ventures
North America, California, United States, Palo Alto
Co-Investments: 3
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Genesys Capital
North America, Ontario, Canada, Toronto
Co-Investments: 5
Foresite Capital
North America, California, United States, San Francisco
Co-Investments: 3
QVT Financial
North America, New York, United States, New York
Co-Investments: 3
Dexcel Pharma
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 3
Alumni Ventures
North America, New Hampshire, United States, Manchester
Co-Investments: 4
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 5

Which angels does JDRF T1D Fund often collaborate with?

PM
North America, Virginia, United States, Charlottesville
Shared Deals: 1

What are some of recent deals done by JDRF T1D Fund?

Aspect Biosystems

Vancouver, British Columbia, Canada

Biotech company developing bioprinted tissue therapeutics to transform how we treat disease.

BiotechnologyLife Science
Series BJan 8, 2025
Amount Raised: $115,000,000
Eledon Pharmaceuticals

Irvine, California, United States

Eledon Pharmaceuticals is a biotechnology company developing treatments for people undergoing organ or cellular transplantation.

BiotechnologyHealth CareMedicalPharmaceutical
Post Ipo EquityOct 29, 2024
Amount Raised: $85,000,000
vTv Therapeutics

High Point, North Carolina, United States

vTv Therapeutics is a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs.

BiotechnologyHealth CareInnovation ManagementPharmaceutical
Post Ipo EquityFeb 28, 2024
Amount Raised: $51,000,000
Cour Pharmaceuticals Development

Skokie, Illinois, United States

Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.

BiotechnologyPharmaceuticalTherapeutics
Series AJan 30, 2024
Amount Raised: $105,000,000
SAB Biotherapeutics

Sioux Falls, South Dakota, United States

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityOct 2, 2023
Amount Raised: $130,000,000
Veralox Therapeutics

Frederick, Maryland, United States

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

BiotechnologyMedicalPharmaceuticalTherapeutics
Series UnknownJun 20, 2023
Amount Raised: $24,000,000
DiogenX

Marseille, Provence-Alpes-Cote d'Azur, France

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

BiotechnologyLife Science
Series AMay 10, 2023
Amount Raised: $36,792,809
Inversago Pharma

Montréal, Quebec, Canada

Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical
Series COct 17, 2022
Amount Raised: $69,264,701
Code Biotherapeutics

Hatfield, Pennsylvania, United States

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

BiotechnologyHealth CareLife Science
Series AJun 7, 2022
Amount Raised: $75,000,000
Kriya Therapeutics

Palo Alto, California, United States

Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.

BiotechnologyHealth CareLife Science
Series CMay 16, 2022
Amount Raised: $270,000,000